Cosmo NVCMOPF -3.22%82 Current Ratio is 7.18 as of Dec. 2025, which is 29% below its 10-year median of 10.07. GuruFocus rates CMOPF with a GF Score™ of 82/100 and a GF Value™ of $54.86 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 998 Drug Manufacturers companies, Cosmo NV ranks better than 91.28% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Cosmo NV's current ratio for the quarter that ended in Dec. 2025 was 7.18.
Cosmo NV has a current ratio of 7.18. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Cosmo NV's Current Ratio or its related term are showing as below:
CMOPF'
s Current Ratio Range Over the Past 10 Years
Min: 1.57 Med: 10.07 Max: 24.38
Current: 7.18
During the past 13 years, Cosmo NV's highest Current Ratio was 24.38. The lowest was 1.57. And the median was 10.07.
CMOPF's Current Ratio is ranked better than 91.28% of 998
companies
in the Drug Manufacturers industry
Industry Median: 1.995
vs CMOPF: 7.18
Cosmo NV (OTCPK:CMOPF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Cosmo NV Current Ratio Related Terms
Cosmo NV Current Ratio Historical Data
* Premium members only.
The historical data trend for Cosmo NV's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Cosmo NV's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo NV Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo NV's Current Ratio distribution charts can be found below:
* The bar in red indicates where Cosmo NV's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo NV (CMOPF) has a Current Ratio of 7.18 as of Dec. 2025. This is 29% below median its historical median of 10.07. Over the past decade, Cosmo NV's Current Ratio has ranged from 1.57 to 24.38. According to the industry distribution chart, Cosmo NV ranks #87 out of 998 companies in the Drug Manufacturers industry, placing it in the top 8.7%.
Is Cosmo NV's Current Ratio too high?
Cosmo NV's current Current Ratio of 7.18 is 29% below median its 10-year median of 10.07. Over the past 10 years, this metric has ranged from a low of 1.57 to a high of 24.38. The Drug Manufacturers industry median Current Ratio is 2.00. Cosmo NV's value of 7.18 is 259.9% above this industry median. Based on the distribution chart, Cosmo NV ranks #87 out of 998 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cosmo NV has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's Current Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Cosmo NV ranks #87 out of 998 companies for Current Ratio. This places Cosmo NV in the top 9% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.00. Cosmo NV's value of 7.18 is 259.9% above this benchmark. Historically, Cosmo NV's own Current Ratio has ranged from 1.57 to 24.38 over the past decade. While the company's 10-year median is 10.07 vs. the industry median of 2.00, Cosmo NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosmo NV's current Current Ratio of 7.18 is 259.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo NV's current Current Ratio is 7.18, which is 29% below median its own 10-year median of 10.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (CMOPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $54.86, compared to a current price of $82.00 — trading 49.5% above its estimated fair value. The current Current Ratio is 7.18, which is 29% below median its 10-year median of 10.07 and 259.9% above the Drug Manufacturers industry median of 2.00. Cosmo NV's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Cosmo NV (CMOPF), the current Current Ratio is 7.18 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo NV (CMOPF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued.
The current stock price of $82.00 is trading 49.5% above its estimated GF Value™ of $54.86.
GuruFocus considers Cosmo NV to be Significantly Overvalued.
Key valuation signals for CMOPF:
Current Ratio: 7.18 (29% below median its 10-year median of 10.07)
GF Value™: $54.86 vs. price of $82.00 (49.5% above fair value)
Industry Position: 259.9% above the Drug Manufacturers median (#87 of 998)
No single metric tells the full story. See the CMOPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
82GF Score
Get the complete analysis for CMOPF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMOPF has been successfully added to your 
